Those in need of nitroglycerin (GTN) therapy who have polymorphism in the mtALDH gene e.g. those of Asian descent for whom this polymorphism is common and/or who are being treated with or ingesting or exposed to mtALDH inhibitor are treated with GTN in combination with agent which converts GTN to product which is metabolized without mtALDH activity e.g. N-acetylcysteine.

Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide e.g. large cell lymphoma or restenosis are treated with a thioredoxin reductase inhibitor e.g. auranofin or arsenic trioxide and a nitric oxide donating compound e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity e.g. Parkinson's disease or se...

FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine and pharmacology and represents pharmaceutical composition for treatment of anal fissures, including base, medication which reduces spasms of smooth muscles, lidocaine, it contains tisolium-gel as base and nifedipine or nitroglycerin as medication, reducing spasm of smooth muscles, components of composition being in specified ratio in grams.EFFECT: invention provides efficient treatment with reduction of concentration of act...

The present invention relates to a protective agent suitable to protect the human skin against toxic materials particularly against chemicals with nucleophilic sites. The active moiety is a polyanhydride derivative. The active transdermal retardant offers a barrier property and chemically and/or physically reacts with harmful chemicals to decrease percutaneous absorption. In the preferred embodiments polyanhydride in its low molecular weight form reduced flux of nicotine and nitrofurazone signif...